| 摘要 |
<p>A new 111In-BLM complex designated 111In-BLMC is described. The complex is characterized by a lack of capacity for binding to serum transferrin, a high selective affinity for viable tumor tissue, in vivo stability, improved activity ratios of tumor to tissues over known 111In-BLM complexes, tumor imaging flexibility and distinctness, and rapid clearance from the body. The new 111In-BLM Complex thus has clinical use as a radiopharmaceutical for combining radiotherapy and chemotherapy, and as a tumor-imaging agent for diagnosis.</p> |
